USING PHARMACOGENOMICS FOR TREATING CARDIOVASCULAR PATIENT



-By Jyoti Singh

INDEX

PROJECT DESCRIPTION:

According to World Health Organisation, Cardiovascular disease is the number 1 cause of death globally i.e More people die annually from CVDs than from any other cause. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and stroke

From the above facts and figures, we can easily conclude that Cardiovascular disease (CVD) accounts for the majority of death and hospitalization, health care expenditures, and loss of productivity in developed country

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. It relies on applied statistics to evaluate genetic data describing natural variation in response to pharmacotherapeutics such as drugs and vaccines.1 These genetic differences can influence how individuals metabolize medications, their susceptibility to adverse effects, and their overall treatment outcomes.

Ultimately, the project aims to leverage data science techniques to uncover genetic markers influencing drug responses in cardiovascular diseases, empowering data scientists to pioneer precision medicine in cardiovascular care. Its goal is to personalize medicine by tailoring drug therapies to an individual's genetic profile and leading to more safer and effective treatments.



BUSINESS MODEL:

Despite advancements in scientific knowledge about drugs and diseases, we still cannot achieve a high degree of accuracy and safety in the management of diseases. A significant portion of cardiovascular care is dependent on prescription drugs, which cost America over 300 billion every year.[4] Cardiovascular disease medications are often influenced by genetically determined drug responses. A better understanding of drug efficacy optimization may greatly improve the cost-effectiveness and safety of cardiovascular health care.[2]

Therefore, the business presents a promising opportunity within a market characterized by a compelling demand for elevated cardiovascular health care, aligning with the imperative need for refined drug efficacy optimization. This, in turn, is poised to yield not only enhanced cost-effectiveness and safety but also favourable financial returns, rendering it a profitable venture.

Project Objectives:

1. **Genetic Profiling:** Perform genetic profiling of cardiovascular patients to identify genetic variations that may impact their drug metabolism, drug response, and susceptibility to adverse drug reactions.
2. **Drug-Genome Interaction Analysis:** Analyze the relationship between patients' genetic variations and their response to commonly prescribed cardiovascular drugs.
3. **Treatment Recommendations:** Develop a personalized treatment recommendation system that utilizes pharmacogenomic data to guide clinicians in selecting the most appropriate drugs, dosages, and treatment strategies for each patient.
4. **Risk Assessment:** Assess the genetic factors contributing to adverse cardiovascular events and side effects of medication to predict and prevent them.
5. **Clinical Implementation:** Establish protocols and guidelines for the integration of pharmacogenomic testing into routine cardiovascular patient care.
6. **Ethical and Legal Considerations:** Address the ethical and legal aspects of incorporating pharmacogenomics into patient care, including issues related to privacy, informed consent, and data security.

Methods:

1. **Genetic Testing:** Use state-of-the-art genomic sequencing technologies to analyze patients' DNA, identifying relevant genetic variants associated with drug metabolism and response.

2. **Data Analysis:** Apply bioinformatics tools to process and interpret the genetic data, focusing on known pharmacogenetic markers and emerging genetic associations with cardiovascular drug response.
3. **Machine Learning Algorithms:** Develop machine learning models that predict optimal treatment options based on an individual's genetic profile and clinical characteristics.
4. **Clinical Trials and Validation:** Conduct clinical trials to validate the effectiveness of pharmacogenomics-guided treatment compared to standard care, collecting data on patient outcomes and cost-effectiveness.

Expected Outcomes:

1. **Improved Treatment Efficacy:** Personalized treatment plans are expected to lead to better patient outcomes, including reduced cardiovascular events and side effects.
2. **Enhanced Patient Safety:** By tailoring medications to a patient's genetic profile, the risk of adverse drug reactions and interactions will be minimized.
3. **Cost Savings:** Pharmacogenomics-guided treatment may lead to more efficient healthcare resource allocation and reduced healthcare costs over the long term.
4. **Advancement of Precision Medicine:** This project will contribute to the field of precision medicine, demonstrating the potential of pharmacogenomics in cardiovascular care.

Budget and Timeline:

The project will require a multi-year budget to cover genetic testing, data analysis, clinical trials, and educational efforts. The timeline is estimated to be three to five years, with ongoing data analysis and refinement of treatment recommendations.

Collaborations:

This project will involve collaboration with geneticists, cardiologists, bioinformaticians, clinical trial coordinators, and ethicists to ensure a comprehensive and well-rounded approach to integrating pharmacogenomics into cardiovascular patient care.

By harnessing the power of pharmacogenomics, this project aspires to usher in a new era of personalized cardiovascular treatment, offering hope to millions of patients by improving both the quality and safety of their care

DATA ANALYSIS:

The data analysis procedure for a project leveraging pharmacogenomics for personalized treatment of cardiovascular patients involves a series of steps to extract meaningful insights from the collected data.



1. **Data Collection and Integration:**
    - Gather genomic data, clinical data, pharmacogenomic data, machine learning models, clinical trial data, and ethical/legal data from various sources. This may include DNA sequencing, electronic health records (EHRs), genetic testing, and clinical trials.
    - Collaborate with clinicians, geneticists, and researchers to gather relevant genetic and clinical data. Ensuring that data is accurate, complete, and properly integrated from various sources.
2. **Data Preprocessing and Cleaning:**
    - Data preprocessing involves cleaning, transforming, and normalizing raw data to ensure its quality and consistency. Handling missing values, addressing data inconsistencies, and preparing the data for analysis.
3. **Data Integration:**
    - Combine the different types of data (genomic, clinical, and pharmacogenomic) to create a comprehensive patient profile.
    - Ensure that data from various sources are linked properly to the same individuals, maintaining data integrity.

4. **Feature Engineering:**

- Identify and extract relevant features from the integrated data. These features could include genetic variants, clinical variables (e.g., age, sex, medical history), and pharmacogenomic data.
- Feature selection techniques may be applied to choose the most informative features for modelling.

5. **Exploratory Data Analysis (EDA):**
    - Use visualization and statistical techniques to identify trends, outliers, and potential variables influencing drug responses.
6. **Model Selection and Development:**
    - Select appropriate machine learning algorithms and build predictive models that link genetic variations to drug responses. Develop machine learning models to predict optimal treatment options based on a patient's genetic profile and clinical data.
    - Train the models using algorithms suitable for classification or regression tasks, such as Random Forest.
7. **Model Interpretation Training and Validation:**
    - Interpreting the models' results to understand how specific genetic variants affect drug responses.
    - Validate the machine learning models using clinical trial data or other independent datasets.
    - Assess the models' accuracy, precision, recall, F1-score, and other relevant performance metrics.
    - Fine-tune models, adjust hyperparameters, and consider cross-validation techniques to improve model generalization.
8. **Communication:**
    - Communicate the findings they present results through visualizations and reports.
    - Ensure that the recommendations are understandable and actionable for healthcare providers.
9. **Iterative Improvement:**
    - Continuously refine their models and analysis techniques as new data becomes available.
    - Establish a feedback loop for clinicians and researchers to provide insights, report any anomalies, and suggest improvements to the project.

Throughout the data analysis procedure, it is crucial to maintain data accuracy, security, and ethical standards, particularly when dealing with patient genetic and clinical data. Regular auditing and compliance with privacy regulations are essential to ensure the safety and privacy of patients and the ethical conduct of the project.

DATA TYPE AND PROCESSING:

Data Type	Description	Processing:
Genetic Data	Includes DNA sequences and genetic variant information	- Data may require preprocessing steps like variant calling, alignment, and annotation to determine the functional impact of genetic variants - Data Collection (DNA sequencing) - Data Preprocessing (cleaning, normalization) - Genetic Variant Annotation (function, associations)
Clinical Data	Includes patient medical histories, demographic information, comorbidities, and treatment records.	- Involve handling missing values, standardizing data formats, and organizing records for analysis. - Data Collection (EHR, clinical notes) - Data Preprocessing (cleaning, normalization)
Drug Response Data	Information on how patients respond to specific cardiovascular medications.	- May require aggregation, normalization, and transformation to match it with genetic and clinical data.
Pharmacogenomic Data	This type of data includes information on genetic variants associated with drug metabolism, response, and adverse reactions.	- Data Collection (genetic testing) - Data Preprocessing (cleaning, normalization) - Feature Extraction (genotype-phenotype associations)
Ethical and Legal Data	Information related to patient consent, data security, and legal aspects of genetic testing.	- Implement data security measures, ensure patient privacy, and adhere to legal and ethical guidelines when handling genetic and clinical data - Data Security Measures - Privacy Protection - Adherence to Ethical and Legal Guidelines

DATA CHARACTERISTICS (4 V'S):

1. **Volume**: The project focused on cardiovascular diseases, the volume of data is substantial. We are working with extensive datasets encompassing genetic, clinical, and drug response information. These datasets may originate from sources such as UK Biobank and the Cardiovascular Genome Phenome Study. The sheer volume of data is essential for conducting comprehensive and statistically significant analyses in pharmacogenomics.
2. **Variety**: In the field of pharmacogenomics, data comes in a wide range of formats. We are dealing with genetic sequences, clinical records, and drug response details. Furthermore, the data can be structured and unstructured, stemming from various sources. Successfully integrating and standardizing such diverse data is a fundamental aspect of our analysis.
3. **Velocity**: The velocity of data generation in our pharmacogenomics project can vary. While genetic data may change at a slower pace, clinical records and drug response data may be updated frequently. In certain scenarios, real-time data processing and analysis are required to keep up with the dynamic nature of the data.
4. **Veracity**: Data quality is a paramount concern in pharmacogenomics. Accurate and complete genetic and clinical data, as well as the credibility of data sources, are pivotal to drawing meaningful conclusions and ensuring patient safety. Upholding the veracity of the data is a critical challenge that we must address throughout our project.

CONCLUSION:

In brief, this project blends genetics, data science, and cardiovascular medicine to reshape drug responses. By unlocking genetic impacts on treatments through advanced analytics, it promises personalized care, spotlighting data science's pivotal role in enhancing cardiovascular health.

This project is significant as it has the potential to revolutionize the treatment of cardiovascular patients, making it more effective, safer, and cost-efficient. It aligns with the broader goal of advancing precision medicine and personalized healthcare, which has the potential to transform medical practice across various specialties.

DATA SOURCE:

https://www.pharmgkb.org/downloads

REFERENCES:

1. Data science approaches to pharmacogenetics Author - N M Penrod, J H Moore https://pubmed.ncbi.nlm.nih.gov/25109795/
2. Artificial intelligence and data science in pharmacogenomics-based drug discovery: Future of medicines Author - Vikas Jhawat, Sumeet Gupta, Monika Gulia, Anroop Nair https://www.sciencedirect.com/science/article/abs/pii/B9780323983525000057?via%3Dihub
3. Pharmacogenomics in Cardiovascular Diseases Caitrin W. McDonough https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344365/
4. Pharmacogenomics in cardiovascular precision medicine Author - Zhou Zhou https://jlpm.amegroups.org/article/view/5803/html
5. https://blogs.sas.com/content/graphicallyspeaking/2019/02/19/graphing-cardiovascular-disease-mortality-data/
6. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2819%2931276-0/fulltext
7.